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Background: Hepatitis B virus infection is a significant health problem. Approximately two billion people worldwide
have chronic Hepatitis B virus infection and over one million die annually. Hepatitis B virus infection and Human
Immunodeficiency Virus co-infection is an emerging concern in the clinical management of patients because of shared
routes of transmission.
Methods: Hospital based cross-sectional study was performed from January to June, 2012 at Goba General Hospital.
Socio-demographic and possible risk factors data from study subjects were collected using pre-test and structured
questionnaire. Venous blood was collected and the serums were tested for Hepatitis B surface antigen and Human
Immune Deficiency Virus using commercially available rapid test kits. Data were entered and analyzed using the SPSS
software package (version15). Binary and multivariable logistic regressions were used to identify factors associated
factors. A p-value of <0.05 was considered statistical significant.
Result: The prevalence of Hepatitis B surface Antigen in this study group was 26 (7.4%). Prevalence of Hepatitis
B Human Immune Deficiency Virus Co-infection was about 9 (42.3%) and about 17 (5.1%) of Human Immuno
Deficiency Virus negative subjects were positive for Hepatitis B surface Antigen. Risk factors like, hospital admission,
multiple sexual partners, HIV status, and unsafe drug injection were found to have significant association with
Hepatitis B surface Antigen on binary logistic regression. However, multiple sexual partners and being positive
for Human Immuno Deficiency Virus infection were the only significantly associated with Hepatitis B Virus on
multivariable logistic regression.
Conclusion: Even though Hepatitis B surface Antigen prevalence is higher among subjects who are Human
Immuno Deficiency Virus positive, screening program has to be started in the hospital for all clients regardless of
their disease status to prevent the potential spread of the infection.
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Viral hepatitis is a major health problem worldwide and
cause acute and/or chronic hepatitis, which can lead to
the development of extensive liver scarring (cirrhosis),
liver failure, liver cancer and death [1,2].
Hepatitis B virus is one of the major diseases that
causes serious public health problem [3]. World Health* Correspondence: asfneg@yahoo.com
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article, unless otherwise stated.Organization estimated that about two billion people
worldwide have been infected with HBV, about 350 mil-
lion people become chronic carriers and over one million
people die each year as a result of acute fulminate liver
disease or HBV induced cirrhosis and liver cancer [4,5].
The burden of HBV infection is highest in sub-Saharan
Africa [6] and the prevalence of HBV infection in Africa is
on average more than 10% [7]. In particular to Ethiopia,
Study conducted in Addis Ababa showed that the mean
prevalence of HBsAg was 7% [8], at Shashamane General
Hospital about 5.7% [9].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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through contact with their blood, body fluids and secre-
tions. The current treatment for Hepatitis B Virus infection
is not curable after the infection progresses to chronic stage
and not economical for individuals in developing countries
like Ethiopia. HBV is also a major occupational hazard
for health workers [10]. Hence, early screening of people
who attend hospitals to know the status of these indi-
viduals for the infection and identifying associated risk
factors are important to undertake effective prevention
and control measures [11].
Methods
Study design and area
A Hospital based cross-sectional study was conducted at
Goba Town located in Bale Zone, South East Ethiopia
from January to June 2012. The study participants were in-
dividuals in the Outpatient Department of Goba General
Hospital during the study period. Goba is a town located
in the Bale Zone of the Oromia Region approximately
446 km South West of Addis. This city has a latitude and
longitude of 7°0′N 39°59′E and an elevation of 2,743 me-
ters above sea level. In this town there is one general hos-
pital that serves a population of Goba Woreda and
surrounding by providing curative and preventive care.
Sample size determination and sampling techniques
The sample size was calculated using single proportion
formula considering the level of confidence 95% (z = 1.
96) and precision of 5% (d =0. 05), since there was no
study conducted in the region, the expected estimated
prevalence of HBV in the area was set at 50% to yield
maximum sample size of 384.
Lottery method was used to recruit subjects for interview
and blood sample collection at the Outpatient Department
during the study period from January to June 2012.
Data collection tool and methods
Pre-tested and structured questionnaire which consist of
social-demographic information, history of exposure to
risk factors in the past years like the history of STI, his-
tory of liver diseases, history of invasive procedures like
tooth extraction, abortion and ear piercing, history of
multiple sexual partner, blood transfusion, history of
hospital admission and contact with family having liver
diseases. HBV vaccination status of the study subjects
also asked during data collection. These data were col-
lected by counselor nurses currently working in the hos-
pital after getting intensive training given to them before
the commencement of data collection.
Specimen collection and processing
After obtaining informed consent, about 5 ml of blood
sample was collected by vein-puncture from each of theparticipants under aseptic conditions from 353 subjects
by experienced laboratory personnel working in the hos-
pital and immediately put in a vacutainer tubes contain-
ing a clot activator. These tubes were numbered and
processed at the time of collection and the assay was
performed within one hour of sample collection.
Serological test
At the site, the HIV status of all study participants was ob-
tained by counsellor nurse using HIV testing algorithm
rapid test kit as (KHB, Shanghai Kehua Bio-engineering
Co., Ltd. China) for screening and positive samples were
re-tested with STAT-PACK. Samples giving discordant re-
sults in the two tests were re-examined using tiebreaker,
(Uni-Gold HIV, Trinity Biotech PLC, Co. Wick low,
Ireland) and the result of this test was considered.
All the serum samples were tested for HBsAg by using
LINEAR HBsAg which is quantitative, lateral flow im-
munoassay was used for detection of HBsAg in serum or
plasma. Samples positive for HBV were re-tested for the
second time by the same method. Samples repeatedly re-
active for HBsAg were considered positive. The subjects
positive for HBV were referred and consulting to the in-
ternal medicine of the Goba Hospital for further evalu-
ation and treatment.
Data quality control
Pretest was conducted before actual data collection to en-
sure the quality of the questionnaire. Trained and experi-
enced laboratory technologist performed laboratory tests.
Quality control of both markers was checked based on the
manufacturer’s kit instructions. In addition, formation of
the coloured band to the control (C) line acts as a proced-
ural control and serves to valid the results.
Study variables
Independent variables includes social demographic factors
and risk factors for HBsAg including history of hospital ad-
mission, history of sexually transmitted infections, multiple
sexual partners, invasive procedures including tooth extrac-
tion, abortion and ear piercing, history of liver disease, con-
tact with people with liver disease, HBV vaccination status
and HIV status of the study subjects. The dependent vari-
able was the prevalence of Hepatitis B Surface Antigen.
Data analysis
The data were cleaned, entered and analysed using com-
puter software (SPSS version 15). The result was summa-
rized using descriptive statistics for social demographic
and risk factor variables of Hepatitis B infection. Mul-
tiple Logistic regressions were used to identify factors
significantly associated with Hepatitis B surface antigen
(HBsAg). Finally, p-value of less than 5% was declared
as significant association.
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The study was conducted after obtaining institutional
ethical clearance from Research and Community Service
of Madawalabu University. After Separate permission
was also obtained from the Goba General Hospital, in-
formation about the study was given to all study partici-
pants and written informed consent was obtained. The
participants were assured that all the information would
be kept in utmost confidentiality and the samples would
be utilized only for research purpose.
Results
Socio demographic characteristics of the study subjects
From the total sample size, 353 were involved making re-
sponse rate of 91.9%. The majority of the participants 246
(69.7%) were from urban and 203 (57.5%) of them wereTable 1 Socio demographic distribution of study subjects
at Goba General Hospital, South East Ethiopia, 2012
Characteristics Number Percentage
Residence Rural 107 30.3
Urban 246 69.7





Sex Male 150 42.5
Female 203 57.5




Religion Muslim 193 54.7
Christian 160 45.3
Ethnicity Oromo 230 65.2
Amhara 97 27.4
Tigre 26 7.4
Occupation Merchant 60 17.0




Governmental employee 38 10.8
No work 4 1.10
Educational status Illiterate 85 24.1
Primary school 153 43.3
Secondary school 77 21.8
Diploma and above 38 10.8females. Among the study subjects, 229 (64.9%) were mar-
ried, 82 (23.2%) were single and 107 (30.3%) of the study
subjects belong to 25–34 years of age (Table 1).
Prevalence’s of HBsAg and distributions of its risk factors
Among 353 study participants tested, HBsAg was de-
tected positive in 26 (7.4%) and 21 found to be positive
for HIV infection. Among 21 clients who were positive
for HIV, 9 (42.8%) were positive for HBsAg and among
322 tested negative for HIV, 17 (5.1%) of them found to
be HBsAg positive respectively.
Regarding History of vaccination, 328 (92.9%) were re-
ported unvaccinated while only 25 (7.1%) reported they
were vaccinated for Hepatitis B infection. Of different
risk factors considered in this study, history of invasive
procedures accounts about 108 (79.4%) followed by his-
tory of multiple partner which accounts about 54
(15.3%). Among subjects reported invasive procedure,
108 (78.3%) reported Tooth extraction, 23 (16.7%) Abor-
tion, 7 (5.1%) reported history of ear piercing. Among
study subjects screened for HIV infection about 21
(5.9%) were found positive for HIV infection (Table 2).Table 2 Prevalence of hepatitis b virus and its risk factors





HBV infection status No 327 92.6
Yes 26 7.4
History of Liver diseases No 306 86.7
Yes 47 13.3




History of STI No 310 87.8
Yes 43 12.2
History of invasive Procedures No 217 61.5
Yes 136 38.5
Unsafe drug injection No 335 94.9
Yes 18 5.1
Multiple partner No 299 84.7
Yes 54 15.3
Blood transfusion No 335 94.9
Yes 18 5.1
HIV status No 332 94.1
Yes 21 5.9
History of hospital admission No 269 76.2
Yes 84 23.8
History of HBV vaccination Unvaccinated 328 92.9
Vaccinated 25 7.1
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were reported unvaccinated while only 25 (7.1%) reported
that they were vaccinated for Hepatitis B infection. Of dif-
ferent risk factors considered in this study, history of inva-
sive procedures accounts about 108 (79.4%) followed by
history of multiple partner which accounts about 54
(15.3%). Among the subjects reported invasive procedure;
108 (78.3%) reported Tooth extraction, 23 (16.7%) Abor-
tion, 7 (5.1%) reported history of ear piercing. Among
study subjects screened for HIV infection, about 21 (5.9%)
were found positive for HIV infection.
In this study, significantly high prevalence of HBsAg
marker was observed among individuals who have history
of hospital admission and Seropositive for HIV infection.
Among 21 HIV positive individuals, 9 (42.8%) were also
positive for Hepatitis B infection. The statistical associ-
ation between the distribution of HBsAg and HIV indi-
cates a significant association (x2: 41.2; OR; 13.8; p; 0.000).
Risk factors like, Hospital admission, multiple sexual
partnerships, HIV Infection and unsafe drug injection
was found to have significant association with hepatitis
B infection on binary logistic regression while HIV infec-
tion status and History of multiple sexual partner found
significantly associated with Hepatitis B virus infection
on multivariable analysis (Table 3).Table 3 Results from multiple logistic regressions on factors a
subjects at Goba General Hospital, South East Ethiopia, 2012
Risk factors COR
Hepatitis immunization No -
Yes Reference gro
History of hospital admission No 3.03
Yes Reference gro
History of blood transfusion No 1.62
Yes Reference gro
History of unsafe injection No 4.0
Yes Reference gro
Multiple partners No 4.0
Yes Reference gro
History of STI No 1.7
Yes Reference gro
Invasive procedure No 1.9
Yes Reference gro
Liver Diseases No 1.6
Yes Reference gro
Contact with family having Liver diseases No 1.8
Yes Reference gro
HIV infection No 0.07
Yes Reference gro
AOR: Adjusted Odds Ratio, CI: Confidence Interval, COR: Crude Odds Ratio, P: p- ValDiscussions
In Ethiopia, data about HBV are scarce, particularly
absent in selected hospital. Hence, the present study
tried to determine the seroprevalence of HBV and asso-
ciated factors among individuals attending Goba General
Hospital for seeking care or other services during the
study period.
In this study, the overall prevalence the rate of hepa-
titis B virus infection among individuals visiting Goba
General Hospital was 7.4% which is higher than finding
reported by Abebe et al. for the general population of
Addis Ababa which was about 6.1% [8]. This difference
might be due to the difference in study participants and
sample size.
In this study, higher HBsAg 9 (42.8%) positivity rate
was observed among HIV positive individuals. This is
comparable with studies done by Burnett et al. indicat-
ing an increased occurrence of HBV among HIV positive
individuals [12]. This could be due to the fact that both
HBV and HIV share common means of transmission
and risk factors and weakened immune systems. How-
ever, in contrast to this study, a study done in Addis
Ababa [13] and study from South Africa [14] shows the
low prevalence rate of HBV among HIV positive individ-
uals. This might be partly due to effect that some HIVssociated with hepatitis b surface antigen among study
P 95% CI P AOR 95% CI
0.998 - 0.998 - -
up
0.008 1.35-6.85 0.214 0.506 0.17-1.48
up
0.54 0.35-7.46 0.322 2.574 0.39-16.72
up
0.021 1.23-13.39 0.894 1.119 0.21-5.89
up
0.021 1.23-13.39 0.001 0.116 0.03-0.39
up
0.260 0.65-5.01 0.588 1.521 0.33-6.93
up
0.100 0.88-4.34 0.094 0.429 0.16-1.15
up
0.360 0.58-4.52 0.713 0.498 0.01-20.53
up
0.260 0.64-5.10 0.661 2.316 0.05-98.47
up
0.000 0.03-0.19 0.000 0.068 0.02-0.23
up
ue.
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elimination of HBsAg [15]. However, this could not be
the entire explanation as HBsAg was still observed in
relatively lower rate among study subjects naïve for
ART [13].
Having a history of multiple sexual partners also found
to be significant with Hepatitis B infection. This is be-
cause mostly this infection occurs among high risk pop-
ulations that include injection drug users, person with
multiple heterosexual patterns [12]. Identified risk fac-
tors like blood transfusion; tooth extraction was not as-
sociated with the infection in our study. This indicates
that health care workers in the selected set up strictly
use aseptic techniques which really help in prevention of
the infection.
Conclusion
Even though Hepatitis B surface Antigen prevalence is
higher among subjects who are Human Immuno Defi-
ciency Virus positive, screening program has to be started
in all health facilities for all clients regardless of their sero-
status to prevent the potential spread of infection.
Recommendations
Health care workers should use personal protective de-
vices while giving a care for the patients regardless of their
disease status to prevent the potential spread of this viral
infection.
Woreda Health Bureaus and other relevant stake-
holders should work on integrating screening program
for HBV infection at the health services like Goba
Hospital to prevent the infection.
Nationwide studies should be conducted to determine
the magnitude of HBV and its risk factors to get enough
information that help for planning policy to take pre-
ventive measures.
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